EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives $26.63 Consensus Target Price from Analysts

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has received a consensus rating of "Buy" from the nine ratings firms that are covering the stock, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $26.63.

Several research analysts have recently issued reports on the company. StockNews.com raised EyePoint Pharmaceuticals to a "sell" rating in a research note on Friday, March 14th. HC Wainwright restated a "buy" rating and set a $22.00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. Chardan Capital reiterated a "buy" rating and issued a $33.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. Finally, Citigroup assumed coverage on EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating and a $33.00 price objective for the company.

Institutional Investors Weigh In On EyePoint Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Summit Investment Advisors Inc. boosted its stake in EyePoint Pharmaceuticals by 39.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company's stock worth $51,000 after buying an additional 1,940 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of EyePoint Pharmaceuticals in the fourth quarter worth approximately $59,000. Virtus ETF Advisers LLC acquired a new position in EyePoint Pharmaceuticals during the fourth quarter worth approximately $67,000. AlphaQuest LLC raised its stake in EyePoint Pharmaceuticals by 13,246.6% during the fourth quarter. AlphaQuest LLC now owns 9,743 shares of the company's stock worth $73,000 after purchasing an additional 9,670 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in shares of EyePoint Pharmaceuticals in the 4th quarter valued at $76,000. Hedge funds and other institutional investors own 99.41% of the company's stock.

EyePoint Pharmaceuticals Stock Performance

EYPT stock traded down $0.17 during trading on Tuesday, reaching $6.37. 805,154 shares of the company were exchanged, compared to its average volume of 889,177. EyePoint Pharmaceuticals has a 52-week low of $3.91 and a 52-week high of $21.26. The company has a market cap of $437.80 million, a P/E ratio of -3.19 and a beta of 1.39. The stock's 50 day moving average price is $5.93 and its 200 day moving average price is $7.75.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last released its quarterly earnings results on Wednesday, March 5th. The company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.10). The firm had revenue of $11.60 million during the quarter, compared to analyst estimates of $11.02 million. EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. As a group, equities research analysts forecast that EyePoint Pharmaceuticals will post -2.13 EPS for the current year.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.